Avalo Therapeutics’ (AVTX) Neutral Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research report report published on Thursday morning,Benzinga reports.

A number of other brokerages also recently issued reports on AVTX. BTIG Research initiated coverage on Avalo Therapeutics in a report on Thursday, December 19th. They set a “buy” rating and a $40.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and set a $18.00 price target on shares of Avalo Therapeutics in a report on Thursday. Finally, Piper Sandler initiated coverage on Avalo Therapeutics in a report on Friday, February 28th. They set an “overweight” rating and a $48.00 price target on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $35.33.

Avalo Therapeutics Price Performance

Avalo Therapeutics stock opened at $7.66 on Thursday. The business’s fifty day simple moving average is $7.45 and its two-hundred day simple moving average is $9.12. Avalo Therapeutics has a 12 month low of $4.60 and a 12 month high of $34.46.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. RA Capital Management L.P. bought a new position in Avalo Therapeutics in the third quarter valued at about $9,186,000. Ikarian Capital LLC lifted its holdings in Avalo Therapeutics by 1,673.0% in the third quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock valued at $9,218,000 after acquiring an additional 915,629 shares during the period. Northern Trust Corp bought a new position in Avalo Therapeutics in the fourth quarter valued at about $168,000. Velan Capital Investment Management LP bought a new position in Avalo Therapeutics in the fourth quarter valued at about $817,000. Finally, Tower Research Capital LLC TRC lifted its holdings in Avalo Therapeutics by 998.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after acquiring an additional 3,754 shares during the period. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.